

World Journal of *Clinical Infectious Diseases*

World J Clin Infect Dis 2011 December 30; 1(1): 1-25





Contents

Bimonthly Volume 1 Number 1 December 30, 2011

EDITORIAL

- 1 What is the purpose of launching the *World Journal of Clinical Infectious Diseases*?
Sundar S
- 4 Statins as antifungal agents
Galgóczy L, Nyilasi I, Papp T, Vágvölgyi C

OBSERVATION

- 11 Antibiotic-resistant bugs in the 21st century: A public health challenge
Taiwo SS

REVIEW

- 17 Regulation of *fim* genes in uropathogenic *Escherichia coli*
Schwan WR

Contents

World Journal of Clinical Infectious Diseases
Volume 1 Number 1 December 30, 2011

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Clinical Infectious Diseases*

APPENDIX I Meetings
I-V Instructions to authors

ABOUT COVER Sundar S. What is the purpose of launching the *World Journal of Clinical Infectious Diseases*?
World J Clin Infect Dis 2011; 1(1): 1-3
<http://www.wjgnet.com/2220-3176/full/v1/i1/1.htm>

AIM AND SCOPE

World Journal of Clinical Infectious Diseases (*World J Clin Infect Dis*, *WJCID*, online ISSN 2220-3176, DOI: 10.5495) is a bimonthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 106 experts in infectious diseases from 35 countries.

WJCID will focus on a broad spectrum of topics on infectious diseases that will cover epidemiology, immune-pathogenesis, genetic factors, host susceptibility to infection, vector control, novel approaches of treatment, molecular diagnostic and vaccines. It will provide a common stage to share the visions, new approaches, most advanced techniques, and to discuss research problems that will help everyone working in the field of various infections to exchange their views and to improve public health. *WJCID* will also focus on broad range of infections like opportunistic infections, zoonotic infections, tropical and neglected tropical diseases, emerging infections, *etc.* and following topics related to these issues: (1) Causative agents discussing various pathogens; (2) Vectors and Mode of transmission; (3) Host-pathogen interaction and immune-pathogenesis of the disease; (4) Epidemiology of the infection and vector control strategies; (5) Genetic factors covering both host and pathogen; (6) Molecular diagnostic techniques vaccines; and (7) Recent advances in cell tissue culture, lab techniques, *etc.* Various other related fields like medical microbiology, pharmacology of herbs, bioinformatics, *etc.* will be included.

FLYLEAF I-II Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Yuan Zhou
Responsible Electronic Editor: Jin-Lei Wang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Jin-Lei Wang
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Clinical Infectious Diseases

ISSN
ISSN 2220-3176 (online)

LAUNCH DATE
December 30, 2011

FREQUENCY
Bimonthly

EDITING
Editorial Board of *World Journal of Clinical Infectious Diseases*
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjcid@wjgnet.com
<http://www.wjgnet.com>

EDITOR-IN-CHIEF
Shyam Sundar, MD, FRCP (London), FAMS, FNA
Sc, FASc, FNA, Professor, Department of Medicine,

Institute of Medical Sciences, Banaras Hindu University,
Varanasi 221005, India

Lihua Xiao, DVM, PhD, Senior Scientist, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Bldg 23, Rm 9-168, MS D66, 1600 Clifton Rd, Atlanta, GA 30333, United States

EDITORIAL OFFICE
Jin-Lei Wang, Director
World Journal of Clinical Infectious Diseases
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjcid@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Co., Limited
Room 1701, 17/F, Henan Building,
No.90 Jaffe Road, Wanchai, Hong Kong, China
Fax: +852-31158812

Telephone: +852-58042046
E-mail: bpg@baishideng.com
<http://www.wjgnet.com>

PUBLICATION DATE
December 30, 2011

COPYRIGHT
© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/2220-3176/g_info_20100722180909.htm.

ONLINE SUBMISSION
<http://www.wjgnet.com/2220-3176office/>

Statins as antifungal agents

László Galgóczy, Ildikó Nyilasi, Tamás Papp, Csaba Vágvolgyi

László Galgóczy, Ildikó Nyilasi, Tamás Papp, Csaba Vágvolgyi, Department of Microbiology, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary

Author contributions: Galgóczy L, Nyilasi I, Papp T and Vágvolgyi C contributed equally to this paper.

Supported by PannonPharma (Pécsvárad, Hungary); and the Hungarian Scientific Research Fund (OTKA), No. PD 83355 (to Galgóczy L)

Correspondence to: László Galgóczy, PhD, Department of Microbiology, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Közép fasor 52, Hungary. galgoczi@gmail.com

Telephone: +36-62-544005 Fax: +36-62-544823

Received: July 12, 2011 Revised: October 17, 2011

Accepted: December 23, 2011

Published online: December 30, 2011

Peer reviewer: Noah Isakov, PhD, Department of Microbiology and Immunology, Ben Gurion University of the Negev, POBox 653, Beer Sheva, Israel

Galgóczy L, Nyilasi I, Papp T, Vágvolgyi C. Statins as antifungal agents. *World J Clin Infect Dis* 2011; 1(1): 4-10 Available from: URL: <http://www.wjgnet.com/2220-3176/full/v1/i1/4.htm> DOI: <http://dx.doi.org/10.5495/wjcid.v1.i1.4>

INTRODUCTION

The incidence of invasive fungal infections (IFIs) is increasing because of the growing number of immunocompromised hosts and the occurrence of antibiotic resistant strains. The major risk factors for these diseases are the administration of broad-spectrum antibiotics, corticosteroids and cytotoxic agents, intravenous catheters, invasive medical procedures, human immunodeficiency virus infection, poorly controlled diabetes mellitus, hematological malignancy, solid organ or bone marrow transplantation, steroid use, metabolic acidosis, deferoxamine therapy, and severe and prolonged neutropenia^[1,2]. Treatment of IFIs is difficult, because the most widely applied antifungal drugs [e.g. amphotericin B (AMB)] for treatment of such disease are relatively toxic and have serious side effects. Therefore, there is a substantial interest in clinically introduced non-antifungal drugs that have potent antifungal activity and/or can act synergistically with antifungal agents to allow a decrease in their therapeutic concentrations. Such compounds would form the basis of a less toxic therapy^[3]. Statins are interesting from this respect, as they have effective antifungal potential against both yeast and filamentous fungi; furthermore, they can be combined with clinically used antifungal agents.

STATINS

History of statins

Statins were discovered as cholesterol lowering drugs in the 1970s, and are the most widely prescribed medications worldwide^[4].

Abstract

Fungal infections are increasing and their treatment is difficult, because the most widely used antifungal drugs are relatively toxic and have serious side effects. Therefore, interest has focused on safely applicable and clinically introduced non-antifungal drugs, which have potent antifungal activity. Statins were originally used as cholesterol lowering agents in human therapy, but recent studies demonstrated their *in vitro* antifungal activity against yeasts and filamentous fungi. This indicated their potential application, alone or in combination with other drugs, in the treatment of such diseases. Their effective concentrations are higher than their maximum achievable serum levels; therefore, the application of statins for the treatment of invasive fungal infections is only possible in combination with antifungal agents. These synergistic combinations establish a basis for a new safely applicable therapy. This review focuses on the antifungal activity of statins alone and in combination with antifungal and non-antifungal drugs, and their possible application in clinical therapy.

© 2011 Baishideng. All rights reserved.

Key words: Statins; Antifungal activity; Drug interaction

Statins are metabolites of microorganisms (mevastatin, MEV; lovastatin, LOV; simvastatin, SIM and pravastatin, PRA) or fully synthetic compounds (atorvastatin, ATO; cerivastatin, CER; fluvastatin, FLV; pitavastatin, PIT; and rosuvastatin, ROS). The natural statins are substituted hexahydronaphthalene lactones. The first described statin, MEV, was isolated as a secondary metabolite of a *Penicillium citrinum* strain. Subsequently, further intensive fungal screenings for similar compounds revealed that a strain of both *Aspergillus terreus* and *Monascus ruber* produce a more efficient statin, LOV^[5]. SIM is a post-methylated derivative of LOV^[6], and PRA was isolated from the fermentation broth of an Actinobacteria species, *Nocardia autotrophica*^[7].

After successful clinical trials of the natural statins, pharmaceutical companies introduced more effective and safer fully synthetic statins. The structures of synthetic statins are dissimilar and are different from the natural statins, except for the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)-like moiety, which is responsible for HMG-CoA reductase inhibition, which, indirectly, results in their cholesterol lowering effects^[8]. FLV was the first fully synthetic statin, followed by ATO, CER, PIT, and ROS^[5]. CER has been withdrawn from the market because of its serious adverse effect (fatal rhabdomyolysis)^[9].

Statins were observed to have unexpected antifungal effects and their potential application in the treatment of fungal diseases has been intensively studied.

Mechanism of statins' effects

Statins are competitive inhibitors of HMG-CoA reductase, which catalyses the conversion of HMG-CoA to mevalonate, a rate-limiting step in the isoprenoid biosynthetic pathway, which is involved in the synthesis of cholesterol in humans and ergosterol in fungi^[10]. Statins compete with the natural substrate for the enzyme's active site, preventing the formation of a functional enzyme structure with reversible binding^[11].

Thus, the effects of statins are connected with the inhibition of the synthesis of important isoprenoids, e.g. farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are important lipid attachments for the γ subunit of heterotrimeric G-proteins^[12], guanosine triphosphate-binding protein Ras, and Ras-like proteins (Rho, Rab, Rac, Ral, or Rap)^[12-14]. Thus, statins act as inhibitors of some G-protein actions and Ras or Ras-like signaling, which affect several important bioprocesses^[15].

Figure 1 summarizes the metabolic pathway of sterols and the impact of statins in their biosynthesis^[16,17].

ANTIFUNGAL ACTIVITY OF STATINS

The *in vitro* antifungal activity of statins against yeasts and filamentous fungal isolates has been frequently reported, and all the studies propose their potential application, alone or in combination, in clinical therapy. The different fungi are not equally sensitive to statins *in vitro*, e.g. SIM




Figure 1 Metabolic pathway of sterols and the impact of statins in their bioprocess^[16,17].

exhibits the strongest antifungal activity against yeasts compared to filamentous fungi, whereas the reverse is true for FLV^[18]. The natural statins (e.g. SIM and LOV) mainly effect their antifungal activity in their active metabolite forms (hydrolysis of the lactone ring at pH 10), and they proved to be less effective as pro-drugs^[18,19]. Generally, the synthetic statins are more effective than the natural ones^[18,19].

Antifungal activity of statins against yeasts

Statins exhibit fungicidal or fungistatic effects against yeasts in a dose dependent-manner. Data concerning the antifungal activity of various statins against yeasts are available for *Candida albicans* (*C. albicans*), *Candida glabrata* (*C. glabrata*), *Candida krusei*, *Candida parapsilosis*, *Candida tropicalis*, *Cryptococcus neoformans* (*C. neoformans*), and *Saccharomyces cerevisiae*^[18,20-29]. These studies demonstrated that the various statins exhibit different antifungal effects against yeasts. SIM displayed the strongest antifungal activity, followed by FLV, ATO, ROS, and LOV. PRA proved to be completely ineffective against them. The antifungal activity of FLV is dependent on the pH of the medium^[27]. Table 1 shows the available minimal inhibitory concentration (MIC) values of the investigated statins against yeast species.

The growth inhibition effect of statins on yeast cells is related to the decreasing ergosterol level, which occurs because of the inactivation of HMG-CoA reductase inactivation by statins in the isoprenoid biosynthetic pathway^[16]. Ergosterol is a main constituent of the lipid layer of fungal plasma membranes, and the antifungal effect might arise from decreased membrane fluidity in the yeast cells^[24]. This assumption is confirmed by the observation that supplementation with ergosterol or cholesterol reduced the antifungal effect of statins^[20,25,26], and that *C. albicans* transformed from the yeast cell form to the

Table 1 Determined minimal inhibitory concentration values ($\mu\text{g/mL}$) of different statins against *Candida* species

Statin/species	ATO	FLV	LOV	PRA	ROS	SIM	Ref.
<i>Candida albicans</i>	128	25-128	5-64	> 128	128	8	[18,21,22,29]
<i>Candida glabrata</i>	32	64-> 128	128	> 128	128	16-32	[18,21,29]
<i>Candida parapsilosis</i>	ND	64-128	ND	ND	ND	ND	[21]
<i>Candida tropicalis</i>	ND	64-128	ND	ND	ND	ND	[21]
<i>Cryptococcus neoformans</i>	ND	16-32	ND	ND	ND	ND	[21]

ATO: Atorvastatin; FLV: Fluvastatin; LOV: Lovastatin; PRA: Pravastatin; ROS: Rosuvastatin; SIM: Simvastatin; ND: Not determined.

Table 2 Determined minimal inhibitory concentration values ($\mu\text{g/mL}$) of different statins against filamentous fungal species

Statin/Species	ATO	FLV	LOV	PRA	ROS	SIM	Ref.
Zygomycetes							
<i>Absidia corymbifera</i>	96 ¹	> 25-3.6	> 96	> 96	33 ¹	96 ¹	[19,35]
<i>Absidia glauca</i>	ND	6.25	ND	ND	ND	ND	[35]
<i>Cunninghamella bertholletiae</i>	ND	ND	32-40	ND	ND	ND	[33]
<i>Micromucor ramanniana</i>	ND	> 25	ND	ND	ND	ND	[35]
<i>Mortierella wolffii</i>	> 128	ND	> 128	ND	> 128	> 128	[34]
<i>Mucor circinelloides</i>	ND	ND	5-40	ND	ND	ND	[33]
<i>Mucor circinelloides f. lusitanicus</i>	ND	> 25	ND	ND	ND	ND	[35]
<i>Mucor hiemalis</i>	ND	> 25	ND	ND	ND	ND	[35]
<i>Mucor mucedo</i>	ND	6.25	ND	ND	ND	ND	[35]
<i>Mucor racemosus</i>	ND	25	ND	ND	ND	ND	[35]
<i>Mycotypha africana</i>	8	ND	> 128	ND	8	> 128	[34]
<i>Paecilomyces variotii</i>	32	25	64	> 128	32	8	[29]
<i>Rhizomucor mieheii</i>	> 96	6.25	64-> 128	> 96	33 ¹	> 96	[19,32,35]
<i>Rhizomucor pusillus</i>	> 96	3.125	1-3.6 ¹	> 96	11 ¹	33 ¹	[19,32,35]
<i>Rhizopus homothallicus</i>	ND	ND	40-56	ND	ND	ND	[33]
<i>Rhizopus microsporus var. oligosporus</i>	> 96	96 ¹	> 96	> 96	> 96	> 96	[19]
<i>Rhizopus oryzae</i>	32-96 ¹	2-11 ¹	32-128	> 128	> 128	64-> 96 ¹	[18,19,29,33,35]
<i>Rhizopus schipperae</i>	ND	> 25	ND	ND	ND	ND	[35]
<i>Rhizopus stolonifer</i>	64		> 128		64	> 128	[34]
<i>Saksenaia vasiformis</i>	ND	> 25	ND	ND	ND	ND	[35]
<i>Syncephalastrum racemosum</i>	32-> 96	33 ¹	16-> 96	> 96	32-> 96	8-> 96	[19,34,35]
Ascomycetes							
<i>Aspergillus flavus</i>	> 128	128	> 128	> 128	> 128	> 128	[18,29]
<i>Aspergillus fumigatus</i>	64-> 256	2	25	> 128	128-> 256	6.25	[18,29,37]
<i>Aspergillus spp.</i>	ND	ND	16-256	ND	ND	4-256	[36]
<i>Paecilomyces variotii</i>	32	25	64	> 128	32	8	[18]
Heterokontophyta							
<i>Pythium insidiosum</i>	ND	16-64	ND	ND	ND	ND	[38]

¹MIC₅₀ value. ATO: Atorvastatin; FLV: Fluvastatin; LOV: Lovastatin; PRA: Pravastatin; ROS: Rosuvastatin; SIM: Simvastatin; ND: Not determined.

pseudomycelial form upon exposure to LOV^[24]. It is also proposed that antimicrobial activity based on the loss of mitochondrial DNA, and thus the respiratory function of the cell, occurs in the presence of statins^[16]. Indirectly, the antifungal effect of statins might come from their negative influence on the cell signaling by the inhibition of the synthesis of lipid attachments for the γ subunit of heterotrimeric G-proteins^[15], and on the cell proliferation and differentiation through inhibition of the synthesis of important isoprenoids^[30]. LOV does not cause apoptotic cell death in yeasts compared to filamentous fungi^[24,31].

Antifungal activity of statins against filamentous fungi

The inhibition activity of statins on the growth of filamentous fungi was revealed in the cases of several zygo-^[18,19,28,31-35] and ascomycetous fungal species^[18,25,28,29,36,37]. Only one article reports the antifungal activity of FLV against a Heterokon-

tophyta fungal species, *Pythium insidiosum*^[38]. In contrast to its activity against yeasts, FLV displayed the strongest antifungal activity, followed by ROS, SIM, LOV, and ATO. PRA also proved to be ineffective against them. Table 2 summarizes the determined MIC values of statins against different filamentous fungal species.

Beyond to the harmful effects on membrane fluidity and the synthesis of important isoprenoids for cell signaling and vital processes (such as cell proliferation and differentiation), and protein prenylation^[16], statins induce apoptosis-like cell death in filamentous fungi^[15,30,31]. The molecular mechanisms underlying the different levels of fungal resistance to statins are unknown. It is hypothesized that the resistance is connected with the different copy numbers of the HMG-CoA reductase gene (*hmgR*) in the case of filamentous species. This assumption is supported by the observation of Lukács *et al.*^[39]. In their

study, heterologous expression of the *Rhizomucor miehei* *hmgR* gene in *Mucor circinelloide* lowered its sensitivity to statins compared to the untransformed strain. Furthermore, supplementation of sterols to the medium reduces the antifungal activity of statins, as in the case of yeasts^[25].

ANTIFUNGAL ACTIVITY OF STATINS IN DRUG COMBINATIONS

Statins are not applicable as single antifungal agents for the treatment of IFI because their MICs are much higher (about 1 order of magnitude) than their maximum achievable concentrations in human serum^[11,40-45]. All the same, they should be promising agents in clinical practice because they can act additively or synergistically with antifungal agents, allowing substantial decreases in their therapeutic concentrations and their side effects^[45]. Such combinations would be advantageous as the basis of a less toxic antifungal therapy^[3].

Combination with antifungal agents

Statins can interact synergistically with azole antifungal agents against yeasts and can reduce their growth significantly. Fluconazole (FCZ) with LOV, and FCZ or itraconazole (ITZ) with FLV, interact synergistically on the growth of *Candida* species^[21,22]; however, interaction was not demonstrated between PRA or FLV and FCZ^[23]. FLV acted additively with AMB, FCZ, and ITZ against *C. albicans* and *C. neoformans*^[21]. Both synergistic and additive effects were observed on the growth reduction of *C. albicans* and *C. glabrata* when primycin (PN), a non-polyene macrolide lactone antibiotic complex, was combined with FLV, LOV, or SIM^[18]. Additive interactions were observed between AMB and ATO and ROS, and between nystatin (NYS) and FLV, LOV, ROS, and SIM in the case of *C. albicans* and *C. glabrata*^[28]. A recent comprehensive study, where the interaction was investigated between four different azole compounds (FCZ; ITZ; ketoconazole, KTZ; and miconazole; MCZ) and six different statins (ATO, FLV, LOV, PRA, ROS, and SIM), revealed synergistic and additive interaction between these compounds against *C. albicans* and *C. glabrata*^[29]. Table 3 summarizes these interactions.

Synergistic and additive interactions were revealed between statins and antifungal agents in the case of zygomycetous fungal species^[18,19,28,29,33]. Significant *in vitro* synergy between statins and azole antifungal agents was demonstrated against several zygomycete fungi, though voriconazole itself was ineffective^[29,33]. Remarkable antifungal effects were observed on the growth of *Rhizopus oryzae* when PN was combined with statins in concentrations that could not inhibit the fungal growth alone^[18]. In the case of this species, AMB and NYS also interacted additively with different statins^[28]. *In vitro*, FLV and ROS acted synergistically and additively with AMB in inhibiting the growth of fungi belonging to Zygomycetes over their clinically available concentration ranges in human serum^[19]. After *in vivo*

tests, these concentration combinations may represent a promising basis for combined therapy in the treatment of invasive zygomycosis.

Synergistic and/or additive interaction of AMB, caspofungin, VCZ, PN with FLV on the growth reduction of *Aspergillus fumigatus* was demonstrated^[28,37]. AMB acted additively with ATO and FLV against *Aspergillus flavus*^[28]. Synergistic interaction was observed between PN and FLV, LOV and SIM, and an additive interaction was observed between AMB and ATO or SIM in the case of *Paecilomyces variotii*^[18,28]. Additive and synergistic interactions were revealed between statins and azoles against *A. flavus*, *A. fumigatus*, and *Paecilomyces variotii*^[29].

Terbinafine acted antagonistically in combination with FLV against *P. insidiosum*. Reduced antifungal activity was observed for their combination compared to when they were applied alone^[38].

Combination with other drugs

Drug interactions were revealed between statins and non-antifungal drugs, which have a secondary antifungal activity. An antifungal peptide secreted by *Penicillium chrysogenum* (*Penicillium chrysogenum* antifungal protein; PAF) and a hex-asulfonated naphthylurea, suramin (originally applied as an agent for treatment of parasitic infections) can decrease the growth of zygomycetous fungal species in the presence of different statins^[34,35]. The activities of the statin-PAF combinations on the different strains varied, and depended on the activities of the components applied separately. When a strain was resistant to one of the components, significant interactions could not be detected. On the other hand, when a strain was sensitive to both types of antifungal agents, synergistic or additive interactions were detected^[34]. Interactions were not detected between FLV and suramin if the investigated strain proved to be insensitive to both compounds, but synergistic and additive interactions could be observed if the fungus was sensitive to FLV and insensitive to suramin. Antagonistic interaction was observed if the fungus was sensitive to both drugs^[35].

These results are summarized in Table 4.

STATINS AS ANTIFUNGAL AGENTS IN CLINICAL THERAPY

A number of studies detail the beneficial effects of statins in transplant or non-transplant recipients with sepsis or infection^[16]. One theory of the possible clinical therapy for invasive mould infection (IMI) among immunocompromised patients was created based on the observation that this disease in patients with diabetes mellitus appears to be decreasing over recent years because of the more frequent use of statins in these patients^[46]. This hypothesis is well supported by the above-mentioned *in vitro* susceptibility and drug interaction studies; however, a recent retrospective case-control study suggested that, despite evidence of *in vitro* activity, statins may not decrease risk of IMI^[47].

In consequence, because the *in vitro* observed MICs

Table 3 Revealed *in vitro* interactions between statins and clinically used antifungal agents against different fungi

Species	Antifungal agent	Statin	Interaction	Ref.
Yeasts				
<i>Candida albicans</i>	AMB	ATO, FLV	ADD	[28,21]
	FCZ, ITZ, KTZ	ATO	ADD	[29]
	FCZ, ITZ	FLV	ADD, SYN, NI	[21,23,29]
		LOV	SYN, ADD	[22,29]
	FCZ, ITZ, KTZ, MCZ	PRA	NI	[23,29]
	FCZ,KTZ	ROS	ADD	[29]
	FCZ, ITZ, KTZ	SIM	ADD	[29]
	ITZ, KTZ, MCZ	FLV, LOV	ADD	[29]
	ITZ,MCZ	ROS	SYN, ADD	[29]
	MCZ	ATO,SIM	SYN, ADD	[29]
	PN, NYS	FLV, LOV, SIM	ADD	[18,28]
	AMB	ATO, ROS	ADD	[18]
	FCZ	ATO	SYN, ADD	[29]
	FCZ, ITZ	FLV	ADD, NI	[21,29]
	FCZ	LOV	SYN, ADD	[29]
<i>Candida glabrata</i>	FCZ, ITZ	PRA	NI	[29]
	FCZ, ITZ, KTZ, MCZ	ROS, SIM	ADD	[29]
	ITZ, KTZ, MCZ	ATO, FLV, ROS	ADD	[29]
	KTZ, MCZ	PRA	ADD	[29]
	PN	ATO, FLV	ADD	[18]
		LOV, SIM	ADD, SYN	[18]
	NYS	LOV, ROS	ADD	[28]
	FCZ, ITZ	FLV	ADD, SYN	[21]
	FCZ	FLV	SYN	[21]
	ITZ	FLV	ADD, SYN	[21]
<i>Candida parapsilosis</i>	FCZ, ITZ	FLV	ADD, SYN	[21]
	FCZ	FLV	SYN	[21]
<i>Candida tropicalis</i>	ITZ	FLV	ADD, SYN	[21]
	FCZ, ITZ	FLV	ADD, SYN	[21]
<i>Cryptococcus neoformans</i>	FCZ, ITZ	FLV	ADD, SYN	[21]
	AMB	FLV	ADD	[21]
Filamentous fungi-Zygomycetes				
<i>Absidia corymbifera</i>	AMB	ROS	ADD, SYN	[19]
<i>Cunninghamella bertholletiae</i>	VCZ	LOV	SYN	[33]
<i>Mucor circinelloides</i>	VCZ	LOV	SYN	[33]
<i>Rhizomucor mieheii</i>	AMB	FLV, ROS	ADD, SYN	[19]
<i>Rhizopus homothallicus</i>	VCZ	LOV	SYN	[33]
<i>Rhizopus microsporus var. oligosporus</i>	AMB	FLV, ROS	ADD, SYN	[19]
<i>Rhizopus oryzae</i>	AMB	FLV, ROS	ADD, SYN	[19,28]
		ATO, SIM	ADD	[28]
	FCZ	FLV	NI	[29]
	FCZ, ITZ, MCZ	LOV	ADD	[29]
	ITZ, KTZ	ATO, FLV, ROS	SYN, ADD	[29]
	ITZ, KTZ, MCZ	PRA	NI	[29]
	ITZ, KTZ	SIM	NI	[29]
	KTZ	LOV	NI	[29]
	MCZ	ATO	NI	[29]
		FLV, ROS, SIM	ADD	[29]
	NYS	ATO, FLV, LOV	ADD	[28]
	PN	ATO	ADD	[18]
		LOV, ROS	SYN	[18]
	VCZ	LOV	SYN	[33]
	AMB	FLV, ROS	ADD, SYN	[28]
<i>Syncephalastrum racemosum</i>				
Filamentous fungi-Ascomycetes				
<i>Aspergillus flavus</i>	AMB, PN	FLV	ADD, SYN	[18,28]
	ITZ	ATO	SYN	[29]
	ITZ, KTZ, MCZ	FLV	SYN, ADD	[29]
	ITZ	LOV	ADD	[29]
	ITZ, KTZ	PRA	NI	[29]
	ITZ	ROS	ADD	[29]
	ITZ, MCZ	SIM	ADD	[29]
	KTZ	ATO, ROS	SYN, ADD	[29]
		SIM	NI	[29]
	MCZ	ATO, LOV, ROS	NI	[29]
		PRA	ADD	[29]
	AMB	ATO, FLV	ADD, SYN	[28,37]
<i>Aspergillus fumigatus</i>	CFG, VCZ	FLV	SYN	[37]
	FCZ, ITZ	ATO	SYN	[29]
	FCZ, ITZ, MCZ	FLV	ADD	[29]
	FCZ	LOV	SYN	[29]

<i>Paecilomyces variotii</i>	FCZ	SIM	SYN, ADD	[29]
	ITZ, KTZ, MCZ	LOV, SIM	ADD	[29]
		PRA	NI	[29]
	ITZ	ROS	SYN, ADD	[29]
	KTZ, MCZ	ATO	SYN, ADD	[29]
	KTZ	FLV	SYN, ADD	[29]
	KTZ, MCZ	ROS	ADD	[29]
	AMB	ATO, SIM	ADD	[28]
	PN	FLV, LOV, SIM	SYN	[18]
Filamentous fungi-Heterokontophyta				
<i>Pythium insidiosum</i>	TBF	FLV	ANT	[37]

ADD: Additive interaction; AMB: Amphotericin B; ANT: Antagonism; ATO: Atorvastatin; CFG: Capofungin; FCZ: Fluconazole; FLV: Fluvastatin; ITZ: Itraconazole; KTZ: Ketoconazole; LOV: Lovastatin; MCZ: Miconazole; NI: No interaction; NYS: Nystatin; PN: Primycin; PRA: Pravastatin; ROS: Rosuvastatin; SIM: Simvastatin; SYN: Synergistic interaction; TBF: Terbinafine; VCZ: Voriconazole.

Table 4 Revealed *in vitro* interactions between statins and non-antifungal drugs against zygomycetous fungi

Species	Non-antifungal drug	Statin	Interaction	Ref.
Zygomycetes				
<i>Absidia corymbifera</i>	SUR	FLV	SYN	[35]
<i>Absidia glauca</i>	SUR	FLV	ANT	[35]
<i>Micromucor ramanniana</i>	SUR	FLV	SYN	[35]
<i>Mucor circinelloides f. lusitanicus</i>	SUR	FLV	ADD, SYN	[35]
<i>Mucor racemosus</i>	SUR	FLV	ANT	[35]
<i>Mycotypha africana</i>	PAF	ATO, SIM	ADD	[34]
		LOV, ROS	ADD, SYN	[34]
<i>Rhizomucor mieheii</i>	SUR	FLV	ANT	[35]
<i>Rhizomucor pusillus</i>	SUR	FLV	ANT	[35]
<i>Rhizopus oryzae</i>	SUR	FLV	ADD, SYN	[35]
<i>Rhizopus schipperae</i>	SUR	FLV	ADD, SYN	[35]
<i>Saksanaea vasiformis</i>	SUR	FLV	ADD, SYN	[35]
<i>Syncephalastrum racemosum</i>	PAF	ATO	ADD, SYN	[34]
		ROS, SIM	SYN	[34]
	SUR	FLV	ADD, SYN	[35]

ADD: Additive interaction; ANT: Antagonism; ATO: Atorvastatin; FLV: Fluvastatin; LOV: Lovastatin; PAF: *Penicillium chrysogenum* antifungal protein; ROS: Rosuvastatin; SIM: Simvastatin; SUR: Suramin; SYN: Synergistic interaction.

of statins are higher than their concentrations achievable in human serum, their potential application to prevent or treat IMIs is only possible in combination with antifungal agents^[45]. In clinical practice, the administration of statins together with antifungals, which are metabolized by different cytochrome P450 (CYP450) isoenzymes in the liver, suggests that the drug interactions with the CYP system and the serious adverse effects (e.g. myopathy) are avoidable^[45].

FUTURE PROSPECTIVES

The number of antifungal agents available for treatment of IFIs is limited, and their use has been restricted because of their toxicity or unfavorable pharmacokinetic profiles^[3]. Hence, research interest has focused on safe, non-antifungal drugs that are used in clinical practice and have antifungal activity.

The observed *in vitro* antifungal activities of statins and their combinations with clinically antifungal agents would create new therapies for the treatment of IFI, without serious side effects. However, there are some factors in their combined application that require increased attention in immunocompromised hosts. As a consequence of the pleiotropic beneficial effects of statins beyond their lipid lowering attributes, there is a decreased risk of chronic renal failure and an improved endothelial dysfunction^[16]. Importantly, the administration of statins together with antifungals that are predominantly metabolized by the same CYP450 isoenzymes in the liver is contraindicated, because such drug interactions with the CYP system may cause serious adverse effects^[45].

Further studies, for example, *in vivo* animal model experiments, are needed to evaluate the practical efficiency and possible triggered side effects of statin-antifungal drug combinations.

REFERENCES

- Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. *Clin Microbiol Rev* 2000; **13**: 236-301
- Nosanchuk JD. Current status and future of antifungal therapy for systemic mycoses. *Recent Pat Antiinfect Drug Discov* 2006; **1**: 75-84
- Afeltra J, Verweij PE. Antifungal activity of nonantifungal drugs. *Eur J Clin Microbiol Infect Dis* 2003; **22**: 397-407
- Lyons KS, Harbinson M. Statins: in the beginning. *J R Coll Physicians Edinb* 2009; **39**: 362-364
- Barrios-González J, Miranda RU. Biotechnological production and applications of statins. *Appl Microbiol Biotechnol* 2010; **85**: 869-883
- Ykema A, Streekstra H, Luiten R, Gijsbertus M. Statin production by fermentation. PCT WO9910499, March 4, 1999
- Okazaki T, Serizawa N, Enokita R, Torikata A, Terahara A. Taxonomy of actinomycetes capable of hydroxylation of ML-236B (compactin). *J Antibiot (Tokyo)* 1983; **36**: 1176-1183
- Manzoni M, Rollini M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. *Appl Microbiol Biotechnol* 2002; **58**: 555-564
- Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. *Curr Control Trials Cardiovasc Med* 2001; **2**: 205-207
- Stancu C, Sima A. Statins: mechanism of action and effects. *J Cell Mol Med* 2001; **5**: 378-387
- Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Ber-

- nini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. *Pharmacol Ther* 1999; **84**: 413-428
- 12 **Liao JK**, Laufs U. Pleiotropic effects of statins. *Annu Rev Pharmacol Toxicol* 2005; **45**: 89-118
- 13 **Liao JK**. Isoprenoids as mediators of the biological effects of statins. *J Clin Invest* 2002; **110**: 285-288
- 14 **Ghittoni R**, Patrussi L, Pirozzi K, Pellegrini M, Lazzerini PE, Capecci PL, Pasini FL, Baldari CT. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. *FASEB J* 2005; **19**: 605-607
- 15 **Cordle A**, Koenigsnecht-Talboo J, Wilkinson B, Limpert A, Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. *J Biol Chem* 2005; **280**: 34202-34209
- 16 **Sun HY**, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. *Clin Infect Dis* 2009; **48**: 745-755
- 17 **Lefebvre M**, Alshawa K, Dupont B. L'activité antifongique des statines. *J Med Mycol* 2010; **20**: 212-217
- 18 **Nyilasi I**, Kocsubé S, Pesti M, Lukács G, Papp T, Vágvölgyi C. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. *J Med Microbiol* 2010; **59**: 200-205
- 19 **Galgóczy L**, Lukács G, Nyilasi I, Papp T, Vágvölgyi C. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. *Acta Biol Hung* 2010; **61**: 356-365
- 20 **Lorenz RT**, Parks LW. Effects of lovastatin (mevinolin) on sterol levels and on activity of azoles in *Saccharomyces cerevisiae*. *Antimicrob Agents Chemother* 1990; **34**: 1660-1665
- 21 **Chin NX**, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against *Candida* species and *Cryptococcus neoformans*. *Antimicrob Agents Chemother* 1997; **41**: 850-852
- 22 **Song JL**, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in *Candida albicans*. *Med Mycol* 2003; **41**: 417-425
- 23 **Nash JD**, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against *Candida albicans*. *J Med Microbiol* 2002; **51**: 105-109
- 24 **Gyetvai A**, Emri T, Takács K, Dergez T, Fekete A, Pesti M, Pócsi I, Lenkey B. Lovastatin possesses a fungistatic effect against *Candida albicans*, but does not trigger apoptosis in this opportunistic human pathogen. *FEMS Yeast Res* 2006; **6**: 1140-1148
- 25 **Macreadie IG**, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of *Candida* species and *Aspergillus fumigatus* by statins. *FEMS Microbiol Lett* 2006; **262**: 9-13
- 26 **Westermeyer C**, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in *Candida glabrata*. *FEMS Yeast Res* 2007; **7**: 436-441
- 27 **Schmidt M**, Dzogbeta S, Boyer MP. Inhibition of *Candida albicans* by Fluvastatin Is Dependent on pH. *Res Lett Biochem* 2009; **2009**: ID 151424
- 28 **Nyilasi I**, Kocsubé S, Galgóczy L, Papp T, Pesti M, Vágvölgyi C. Effect of different statins on the antifungal activity of polyene antimycotics. *Acta Biol Szeged* 2010; **54**: 33-36
- 29 **Nyilasi I**, Kocsubé S, Krizsán K, Galgóczy L, Pesti M, Papp T, Vágvölgyi C. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. *FEMS Microbiol Lett* 2010; **307**: 175-184
- 30 **Miida T**, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. *J Atheroscler Thromb* 2004; **11**: 253-264
- 31 **Roze LV**, Linz JE. Lovastatin triggers an apoptosis-like cell death process in the fungus *Mucor racemosus*. *Fungal Genet Biol* 1998; **25**: 119-133
- 32 **Lukács G**, Papp T, Nyilasi I, Nagy E, Vágvölgyi C. Differentiation of *Rhizomucor* species on the basis of their different sensitivities to lovastatin. *J Clin Microbiol* 2004; **42**: 5400-5402
- 33 **Chamilos G**, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. *Antimicrob Agents Chemother* 2006; **50**: 96-103
- 34 **Galgóczy L**, Papp T, Lukács G, Leiter E, Pócsi I, Vágvölgyi C. Interactions between statins and *Penicillium chrysogenum* antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. *FEMS Microbiol Lett* 2007; **270**: 109-115
- 35 **Galgóczy L**, Papp T, Vágvölgyi C. In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. *Mycoses* 2009; **52**: 447-453
- 36 **Qiao J**, Kontoyiannis DP, Wan Z, Li R, Liu W. Antifungal activity of statins against *Aspergillus* species. *Med Mycol* 2007; **45**: 589-593
- 37 **Natesan SK**, Chandrasekar PH, Alangaden GJ, Manavathu EK. Fluvastatin potentiates the activity of caspofungin against *Aspergillus fumigatus* in vitro. *Diagn Microbiol Infect Dis* 2008; **60**: 369-373
- 38 **Cavalheiro AS**, Zanette RA, Spader TB, Lovato L, Azevedo MI, Botton S, Alves SH, Santurio JM. In vitro activity of terbinafine associated to amphotericin B, fluvastatin, rifampicin, metronidazole and ibuprofen against *Pythium insidiosum*. *Vet Microbiol* 2009; **137**: 408-411
- 39 **Lukács G**, Papp T, Somogyvári F, Csérnetics A, Nyilasi I, Vágvölgyi C. Cloning of the *Rhizomucor miehei* 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in *Mucor circinelloides*. *Antonie Van Leeuwenhoek* 2009; **95**: 55-64
- 40 **Kajinami K**, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. *Cardiovasc Drug Rev* 2003; **21**: 199-215
- 41 **Bellosta S**, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. *Circulation* 2004; **109**: III50-III57
- 42 **Corsini A**, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. *Am J Cardiol* 2005; **96**: 44K-49K; discussion 34K-35K
- 43 **Schachter M**. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fundam Clin Pharmacol* 2005; **19**: 117-125
- 44 **Buemi M**, Floccari F, Nostro L, Campo S, Caccamo C, Sturiale A, Aloisi C, Giacobbe MS, Frisina N. Statins in the prevention of cardiovascular events in patients with renal failure. *Cardiovasc Hematol Disord Drug Targets* 2007; **7**: 7-13
- 45 **Galgóczy L**, Nyilasi I, Papp T, Vágvölgyi C. Are statins applicable for the prevention and treatment of zygomycosis? *Clin Infect Dis* 2009; **49**: 483; author reply 484-485
- 46 **Kontoyiannis DP**. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. *Clin Infect Dis* 2007; **44**: 1089-1090
- 47 **Thompson JN**, Huycke MM, Greenfield RA, Kurdgelashvili G, Gentry CA. Case-control study of statin prevention of mould infections. *Mycoses* 2011; **54**: e481-e485

S- Editor Wang JL L- Editor Stewart G E- Editor Zheng XM